Myeloma

Top Story

FDA grants anti-BCMA CAR-T orphan drug designation for advanced multiple myeloma

FDA grants anti-BCMA CAR-T orphan drug designation for advanced multiple myeloma
March 19, 2020
In the Journals

VTE risk substantial, despite thromboprophylaxis, with lenalidomide-based regimens for multiple myeloma

March 13, 2020
Patients with multiple myeloma who received lenalidomide-based regimens appeared to have considerable risk for venous thromboembolism, regardless of adequate…

Phase 3 trial for transplant-ineligible myeloma misses endpoint

March 11, 2020
A randomized phase 3 trial designed to evaluate the addition of ixazomib to lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma ineligible…

Trial of three-agent combination for multiple myeloma misses endpoint

March 9, 2020
A randomized phase 3 trial designed to evaluate the addition of elotuzumab to lenalidomide and low-dose dexamethasone for a subset of patients with multiple myeloma…
More Headlines »
CME

Picking a PI in MM: Asking & Answering the W5

Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Takeda Oncology.

More »
Video

Baseball Hall of Famer Mike Schmidt ‘paying it forward’ through campaign to support patients with cancer

September 21, 2017
More »
CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

More »